Print

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra

Clinicaltrials.gov identifier:
NCT04644068 (https://clinicaltrials.gov/show/NCT04644068)


Advanced ovarian, breast, prostate or pancreatic cancer

About the Study

NOTE: This study is no longer recruiting people. 

PETRA is a study of a new, investigational PARP inhibitor, AZD5305 taken orally, either alone or combined with other anti-cancer therapies in patients with advanced ovarian, breast, prostate or pancreatic cancer with an inherited mutation in one of the following genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D. The combination available and which group you are assigned to will depend on your cancer type and mutation and when you join the study.

This Study is Open To:

NOTE: This study is no longer recruiting people.

 

This Study is Not Open To:

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.